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Abstract
Background: Extracts from the rhizome of Cimicifuga racemosa (black cohosh) are increasingly
popular as herbal alternative to hormone replacement therapy (HRT) for the alleviation of
postmenopausal disorders. However, the molecular mode of action and the active principles are
presently not clear. Previously published data have been largely contradictory. We, therefore,
investigated the effects of a lipophilic black cohosh rhizome extract and cycloartane-type
triterpenoids on the estrogen receptor positive human breast cancer cell line MCF-7.
Results:  Both extract and purified compounds clearly inhibited cellular proliferation. Gene
expression profiling with the extract allowed us to identify 431 regulated genes with high
significance. The extract induced expression pattern differed from those of 17β-estradiol or the
estrogen receptor antagonist tamoxifen. We observed a significant enrichment of genes in an anti-
proliferative and apoptosis-sensitizing manner, as well as an increase of mRNAs coding for gene
products involved in several stress response pathways. These functional groups were highly
overrepresented among all regulated genes. Also several transcripts coding for oxidoreductases
were induced, as for example the cytochrome P450 family members 1A1 and 1B1. In addition, some
transcripts associated with antitumor but also tumor-promoting activity were regulated. Real-Time
RT-PCR analysis of 13 selected genes was conducted after treatment with purified compounds –
the cycloartane-type triterpene glycoside actein and triterpene aglycons – showing similar
expression levels compared to the extract.
Conclusion: No estrogenic but antiproliferative and proapoptotic gene expression was shown for
black cohosh in MCF-7 cells at the transcriptional level. The effects may be results of the activation
of different pathways. The cycloartane glycosides and – for the first time – their aglycons could be
identified as an active principle in black cohosh.
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Background
Cimicifuga racemosa (L.) NUTT. (syn. Actaea racemosa;
black cohosh, family Ranunculaceae) is a North American
perennial herb which has been traditionally used by
Native Americans for the treatment of rheumatism, dys-
pepsia, epilepsy, kidney ailments, dysmenorrhoea and the
relief of pain during menses and childbirth [1,2]. Since
the 1950s, phytopharmaceuticals containing black
cohosh extracts from the rhizome are used for the allevia-
tion of menopausal disorders [3]. Since the Women's
Health Initiative (WHI) described adverse effects of hor-
mone replacement therapy (HRT) such as increased risk of
breast cancer and cardiovascular diseases [4], the popular-
ity of herbal alternatives such as black cohosh has consid-
erably increased.
The phytochemicals in black cohosh rhizomes have been
well studied, and numerous cycloartane-type triterpene
glycosides (e.g. actein Figure 1), aromatic acids (e.g. caf-
feic and ferulic acid), cinnamic acid esters (e.g. fukinolic
acid, cimicifugic acids) and various minor compounds
have been reported [1,2,5]. The pharmacology of rhizome
extracts has been investigated, whereby most investiga-
tions addressed the effects on the hormonal (estrogenic)
system. An estrogen-like activity was reported initially [6-
8], but these effects could not be confirmed in later studies
[8-11]. Subsequently, antiestrogenic properties were pro-
posed on the basis of in vitro experiments [8,12,13].
Because a black cohosh extract influenced bone,
endometrium and hypothalamus, but not uterus in a
estrogen-like manner, it was postulated to contain com-
pounds that act as selective estrogen receptor modulators
(SERMs) and, therefore, to be different from common
phytoestrogens – a presumption that is still a matter of
dispute [14-17].
In binding studies black cohosh extracts showed no affin-
ity to estrogen receptors α and β (ERα/β), progesterone
(PR) or androgen receptor (AR) [10,16,18,19], but weak
affinity towards the aryl hydrocarbon receptor (AhR)
[20,21]. Most recently, treatment of human breast cancer
MCF-7 cells with black cohosh extracts and with fractions
containing cycloartane glycosides and cinnamic acid
esters, respectively, resulted in antiproliferative effects and
induction of apoptosis [22,23]. Incubation of MCF-7 cells
with a fraction containing the cycloartane glycosides led
to cell cycle arrest at the G1/S- and, to a lesser degree, at
the G2/M-transition points, and treatment with actein
affected expression levels of some proteins, such as p21, in
a G1-arresting manner [24].
Finally, irrespective of the putative estrogenic activity
recent investigations reporting dopaminergic [16,25],
serotoninergic [26,27] and opioidic action [28] of black
cohosh extracts provide evidence, that the beneficial
effects such as reduction of hot flashes may be due to neu-
rotransmitter and CNS activity.
Despite all these studies, the mode of action of black
cohosh extracts and the nature of the active principles are
presently not clear.
A major limitation of all these studies was that they were
always conducted in a very specific perspective, while
other possible modes of action were ignored. With the
emergence of microarrays as a mature technology obser-
vation of global drug effects at gene expression level has
become possible. This led us to perform a genome-wide
gene expression profiling experiment to measure global
effects of black cohosh at the mRNA level. For the study
we used the ERα-positive human breast cancer cell line
MCF-7, a widely used in vitro model for investigations of
(anti)estrogenic effects and estrogen-dependent breast
cancer. MCF-7 cells were treated with a lipophilic black
cohosh extract. The rationale behind using this extract was
that ligands for nuclear receptors such as the estrogen
receptors are lipophilic molecules. Parallel experiments
were carried out with 17β-estradiol (E2) and the estrogen
receptor antagonist tamoxifen to compare expression pro-
files with these drugs. Gene expression was determined
using whole-genome Affymetrix GeneChip®  Human
Genome U133 Plus 2.0 Array, which represents about
38500 genes. Microarray results for selected genes were
confirmed by real-time RT-PCR analysis. This method was
also used to analyze the effects of actein, the major
cycloartane glycoside in the rhizomes, and a mixture of
cycloartenol aglycons. The latter was prepared to mimic a
likely enzymatic hydrolysis of the glycosides in the gas-
trointestinal tract prior to absorption.
Methods
Extract
Rhizomes of black cohosh (Cimicifugae racemosae rhi-
zoma) were obtained from Caesar&Loretz (Hilden, Ger-
Chemical structure of Actein, the major cycloartane-type  triterpene glycoside of black cohosh Figure 1
Chemical structure of Actein, the major cycloartane-type 
triterpene glycoside of black cohosh.BMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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many, lot number 82044149). Powdered rhizome (0.5
mm particle size, 10 g) were subjected to pressurized liq-
uid extraction using an ASE®200 Accelerated Solvent
Extractor (Dionex, Sunnyvale, CA) at 120 bar and 70°C.
After a preheating step (5 min), the sample was defatted
with petroleum ether (5 min), followed by extraction with
dichloromethane for 10 min. Solutions were collected in
different vials. The petroleum ether solution was dis-
carded. After evaporation of the solvent, 350 mg of dry
dichloromethane extract was obtained.
Compounds
The mixture of cycloartenol aglycons was obtained as fol-
lows: A dichloromethane extract of black cohosh rhizome
(2 kg) was prepared by maceration at room temperature
for 24 h. The extract (25.5 g) was separated on a silica gel
column (40–63 µm, 70 × 5 cm i.d.) using a step gradient
of CHCl3-MeOH-H2O (90:9.5:0.5), CHCl3-MeOH-H2O
(70:30:3) and methanol. Fractions were combined on the
basis of their TLC pattern. Fractions containing cycloar-
tane glycosides were combined in equal proportions (250
mg each) and dissolved in methanol. After addition of 1
N HCl, the solution was refluxed for 1 h. Aglycons were
extracted by partitioning with chloroform. The chloro-
form extract was evaporated to dryness, and the residue
(340 mg) was purified by chromatography on a Sepha-
dex® LH20 (Pharmacia, Uppsala, Sweden) column, eluted
with methanol to afford 120 mg of aglycon mixture.
Actein was purchased from Phytoplan (Heidelberg, Ger-
many), 17β-estradiol from Sigma-Aldrich (Taufkirchen,
Germany) and tamoxifen from MP Biomedicals
(Eschwege, Germany).
For subsequent experiments extract and compounds were
dissolved in dimethyl sulfoxide (DMSO) and diluted with
appropriate assay media. The final concentration of
DMSO did not exceed 0.1%. This concentration was also
used for control experiments.
Cell culture
The human breast adenocarcinoma cell line MCF-7
(obtained from ATCC) was routinely cultured in Dul-
becco's Modified Eagle's Medium (DMEM) containing
10% fetal bovine serum (FBS) and Penicillin/Streptomy-
cin (100 U/100 µg/ml) (Biochrom, Berlin, Germany) in a
humidified incubator at 37°C and 5% CO2. Before reach-
ing confluence, cells were splitted every 3–4 days in a 1:4-
to 1:6-ratio. All experiments were performed with cells at
passage numbers 25–33.
Hormone-free charcoal-dextran stripped serum (CSS) was
prepared from FBS by agitating with 0.5% charcoal (Norit
A) (Serva Feinbiochemica, Heidelberg, Germany) and
0.05% Dextran-T70 (Pharmacia) at 37°C for 60 min.
After centrifugation at 3500 rpm CSS was filter-sterilized
(0.22 µm) twice and stored at -20°C.
Proliferation assay
MCF-7 cells were seeded in 96-well microtitre plates
(Greiner Bio-One, Frickenhausen, Germany) with a den-
sity of 3500 cells per well under culture conditions and
incubated at 37°C and 5% CO2. After 24 hours medium
was removed, cells were washed with phosphate-buffered
saline (PBS), and phenol red-free DMEM (Gibco™, Invit-
rogen, Karlsruhe, Germany) supplemented with 10% CSS
and test substances in concentrations indicated in the text
were added. Medium was exchanged after 72 hours. After
120 hours cells were quantified by MTT assay [29,30] as
follows. Medium was removed and 100 µl MTT (Fluka,
Buchs, Switzerland), dissolved in phenol red-free DMEM
at 0.5 mg/ml, were added to each well. The plates were
incubated at 37°C and 5% CO2 for 4 hours. Formazan
crystals were solubilized by addition of 100 µl of 20%
sodium dodecylsulfate (SDS) in H2O followed by incuba-
tion overnight at 37°C. Optical density was measured at
544 nm using a microplate reader (Galaxy FluoStar, BMG
Labtechnologies, Offenburg, Germany) with background
substraction. Relative proliferation values were calculated
as percentage of negative control (0.1% DMSO value =
100%). Experiments were repeated at least three times
with 4 to 6 replicates per test concentration. The results are
given as mean value ± standard deviation (SD). Data were
analyzed by Student's t-test. Statistically significance vs.
DMSO control is represented as *(p < 0.05), **(p < 0.01)
or ***(p < 0.001).
The acute cytotoxic potential of black cohosh extract,
actein and the aglycons was determined with the Cytotox-
icity Detection Kit (LDH) (Roche Diagnostics, Man-
nheim, Germany). No acute cytotoxicity could be found
for the extract at concentrations of up to 70 µg/ml, and up
to 100 µM for actein and the aglycons, respectively.
RNA isolation
MCF-7 cells were seeded in 75 cm2 culture flasks (Greiner
Bio-One) at a density of 20000 cells/cm2 under culture
conditions and incubated at 37°C and 5% CO2. After 20
hours medium was removed and cells were washed with
PBS. Phenol red-free DMEM containing 10% CSS and
0.1% DMSO, 15 µg/ml black cohosh extract, 20 µM
actein, 30 µM aglycons, 1 nM 17β-estradiol or 10 µM
tamoxifen, respectively, were added. Cells were incubated
for 24 hours at 37°C and 5% CO2. Cells were washed
twice with PBS and total RNA was extracted from cells
using the RNeasy Mini Kit (Qiagen, Hilden, Germany)
including on column DNase digestion according to the
standard protocol. Quantity and purity of the obtained
total RNA samples were determined by UV spectroscopy.
RNA quality was controlled by gel electrophoresis onBMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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1.5% agarose, stained with ethidium bromide (1 µg/ml).
RNA was stored at -80°C until use.
Array hybridization
Total RNA from each sample was labelled and hybridized
to an Affymetrix GeneChip® Human Genome U133 Plus
2.0 array (Affymetrix, Santa Clara, CA) according to the
manufacturer's protocol (manual version 700217 rev 3),
with minor modification. Briefly, 5 µg of total RNA was
converted into cDNA by using the T7-(dT)24  Primer
(Affymetrix Inc), T4gp32 (USB Corporation, Cleveland,
OH) and the SuperScript II reverse transcriptase for cDNA
synthesis (Invitrogen). Double-stranded cDNA was syn-
thesized, cleaned and extracted with phenol/chloroform,
followed by ethanol precipitation. Resulting cDNA was
resuspended in 12 µl RNase-free water. From the ds-cDNA
template biotin-labeled cRNA was made with the Enzo
High Yield RNA Transcript labeling kit (Enzo Diagnostics,
Farmingdale, NY). The labeled cRNA was purified follow-
ing the Qiagen RNeasy Clean up protocol (Qiagen) and
concentrated to 24 µl by ethanol precipitation. Fragmen-
tation of the biotinylated cRNA (20 µg) was done directly
before hybridization to the microarray. Hybridizations
and scanning were performed at the Affymetrix GeneChip
Core facility of the Medical Faculty, University of Leipzig.
On-chip labeling was done with phycoerythrin-conju-
gated streptavidin. After final washing steps fluorescence
was detected with the Affymetrix GeneChip 3000 7G scan-
ner.
Primary data analysis
Initial data analysis was performed using the Affymetrix
Microarray Suite v5.1 software, setting the scaling of all
probe sets to a constant value of 500 for each GeneChip.
Because of the better implemented normalisation algo-
rithm data were further normalized using RMA-Express
software [31-33]. With RMAExpress all arrays were visu-
ally checked. There were no obvious failures on the chips.
RMAExpress is using an enhanced quantile normalization
[31,32]. All 8 experiments (4 different treatments – black
cohosh extract, estradiol, tamoxifen and DMSO – in
duplicate) were normalized together. Data were then
exported to MS-Excel sheets. We used both the log as well
as the natural output. All further comparisons and analy-
ses are based on these RMAExpress outputs. Clearly regu-
lated (= differentially expressed) genes were determined
using the following criteria: (I) The signal intensity is
higher than the median of all signal intensities on the
array and (II) in both independent duplicate experiments
the fold change vs. DMSO control is larger than 1.5.
Real-time RT-PCR
Expression levels of 14 selected genes were determined by
a two step real-time RT-PCR using the LightCycler® system
(Roche). Total RNA (5 µg) from each sample was tran-
scribed into cDNA with SuperScript III reverse tran-
scriptase (Invitrogen) and a 1:1-mixture of random
hexamers (Promega, Mannheim, Germany) and oligo-
dT(20) primers (MWG Biotech, Ebersberg, Germany) fol-
lowing the standard protocol. Resulting cDNAs were
diluted to a total volume of 100 µl with water (PCR-
grade). The reaction mixture for real-time PCR consisted
of LightCycler® Fast Start DNA MasterPLUS SYBR Green I
Master Mix (Roche), cDNA and 0,5 µM specific forward
and reverse primers (MWG Biotech) for the genes listed in
Table 1. The protocol included an initial denaturation
step at 95°C for 10 min, followed by 5 cycles at 95°C for
5 s, 57°C for 10 s and 72°C for 17 s and finally 45 cycles
at 95°C for 5 s, 59°C for 10 s and 72°C for 17 s. Ratios
between sample and control experiments were calculated
after normalization of expression values to the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). All RT-PCR expression values were determined
at least three times from 2 independent biological experi-




We first performed a MTT-based proliferation assay to
explore how the black cohosh extract and the selected
compounds influence growth of MCF-7 cells. 17β-estra-
diol, the positive control, significantly stimulated cell pro-
liferation after 120 h, reaching a plateau of maximal
stimulation (184.2 ± 28.1% vs. DMSO control; p < 0.001)
at a concentration of 1 nM. The magnitude was compara-
ble to effects observed in other studies with MCF-7
(ATCC) cells [11,34,35]. At a concentration of 10 µM
tamoxifen reduced cell proliferation to 45.7 ± 6.8% (p <
0.001 vs. DMSO control). Exposure of MCF-7 cells for 120
h to different concentrations of black cohosh extract, the
cycloartane glycoside actein and the cycloartane aglycon
mixture all inhibited cell proliferation in a dose-depend-
ent manner (Figure 2). IC50 values – the concentrations
that caused 50% inhibition of growth – were determined
by extrapolation for black cohosh extract (14.7 ± 2.6 µg/
ml), actein (19.6 ± 3.1 µM) and the aglycon mixture (30.3
± 0.5 µM). These proliferation and cytotoxicity measure-
ments provide only a preliminary information of biologi-
cal activity.
Gene expression microarray analysis with black cohosh 
extract
General results
For gene expression profiling MCF-7 cells were treated
with 15 µg/ml black cohosh extract, 1 nM 17β-estradiol,
10 µM tamoxifen or DMSO control for 24 h in the pres-
ence of 10% charcoal stripped serum. After RNA extrac-
tion, gene expression profiles were recorded using
Affymetrix HG U133 Plus 2.0 GeneChip Arrays asBMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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described. Regulated (differentially expressed) genes were
identified using the following selection criteria: minimal
signal intensity > median and fold change vs. control > 1.5
in two independent experiments. With these criteria we
identified 544 probe sets (~1% from the more than 54000
probe sets on the HG U133 Plus 2.0 Array) representing
431 genes regulated by the extract. The false positive rate
with the criteria used is about 5% based on random per-
mutation analysis of the gene expression results, showing
a mean of 22 to 32 regulated probe sets (22/544 ~ 4.0%;
32/544 ~ 5.9%).
Of the genes regulated by the extract, 335 transcripts
(78%) were upregulated and 96 genes (22%) were down-
regulated. These genes were grouped into functional cate-
gories according to Gene Ontology terms and gene
description at the NetAffx™ Analysis Center [36] and addi-
tion literature search. Most of the regulated genes could be
clearly assigned to 5 larger groups of functionally related
genes (subgroups in brackets): apoptosis, proliferation (cell
cycle, replication), general growth (RNA processing, protein
turnover, transcription, cell structure and organization), signal-
ing & transport (signal transduction, transport) and metabo-
lism  (oxidoreductases,  biosynthesis and catabolism). Genes
that could not be assigned to any of these groups were
summarized as others (Figure 3). Furthermore, because of
a striking presence of many transcripts linked to cellular
stress response, we also created the functional category
stress response, which is not directly linked to the other cat-
egories. Genes functionally connected to this group are
already members of one of the 6 main categories (Figure
3). In most groups more genes were stimulated than
inhibited. In the group proliferation, in contrast, a majority
of genes appeared to be downregulated. Genes for this cat-
egory as well as the groups/subgroups apoptosis, protein
turnover, oxidoreductases and stress response are all statisti-
cally overrepresented among the black cohosh regulated
genes (p < 0.001, two-sided p-value Fisher Exact Test). For
two groups – proliferation (cell cycle, DNA replication) and
stress response – the overrepresentation is very highly sig-
nificant.
Regulation of 13 genes representing the 6 functional cate-
gories,  apoptosis,  proliferation,  general growth,  signaling &
transport, metabolism and others, were verified by real-time
RT-PCR from independent samples to confirm the regula-
tion of genes connected to the major cellular effects
observed.
Table 1: Primers used for real-time RT-PCR
Gene Primer Sequence 5'-3' Product Size
Baculoviral IAP repeat-containing 5 (BIRC5) for AAAGCATTCGTCCGGTTG 152 bp
rev CCGCAGTTTCCTCAAATTCT
Cyclin E2 (CCNE2) for GACTGCTGCTGCCTTGTG 151 bp
rev AAAAGTCTTCAGCTTCACTGGA
Cyclin G2 (CCNG2) for CCCAGAACCTCCACAACAG 158 bp
rev GGTGCACTCTTGATCACTGG
Cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) for TCTTCGCTACCTACCCAACC 196 bp
rev ATCTGACAGCTGGACATTGG
Cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1) for AGAACGTACCGGCCACTATC 175 bp
rev GGCTGGTCACCCATACAAG
DNA-damage-inducible transcript 4 (DDIT4) for GTTTGACCGCTCCACGAG 166 bp
rev CATCAGGTTGGCACACAAGT
DnaJ (Hsp40) homolog, subfamily B, member 9 (DNAJB9) for GGATGCTGAAGCAAAATTCA 150 bp
rev AATGACTGCTCAAAAGAACTTCC
E2F transcription factor 2 (E2F2) for CGCATCTATGACATCACCAAC 157 bp
rev TGTTCATCAGCTCCTTCAGC
Estrogen receptor, alpha (ESR1) for CAGACACTTTGATCCACCTGA 179 bp
rev CTCCAGCAGCAGGTCATAGA
GREB1 protein (GREB1) for ATCATCCTGAACGTGGACCT 151 bp
rev CCACGATCTGCTTCTTCATC
Growth arrest and DNA-damage-inducible, alpha (GADD45A) for GGAGGAAGTGCTCAGCAAA 169 bp
rev CTGGATCAGGGTGAAGTGG
Metastasis associated in lung adenocarcinoma transcript 1 (MALAT-1) for TGCAATTTGGTGATGAAGGT 161 bp
rev CAACATATTGCCGACCTCAC
Proliferating cell nuclear antigen (PCNA) for TTGCACTGAGGTACCTGAACTT 160 bp
rev CCTTCTTCATCCTCGATCTTG
Vascular endothelial growth factor (VEGF) for CATCTTCAAGCCATCCTGTG 179 bp
rev TGCATTCACATTTGTTGTGC
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for ACCAGGTGGTCTCCTCTGAC 173 bp
rev TTACTCCTTGGAGGCCATGTBMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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The cellular effects of the functional groups regulated by
black cohosh are summarized in Figure 4. Expression val-
ues of selected genes are presented in Table 2. A complete
list of all regulated genes is available [see Additional file
1]. The data discussed in this publication have also been
deposited in NCBIs Gene Expression Omnibus (GEO)
[37], and are accessible through GEO Series accession
number GSE6800.
Proliferation
In agreement with the anti-proliferative effect of the black
cohosh extract, genes involved in proliferation control
were significantly overrepresented. Transcripts related to
cell cycle regulation and DNA replication were regulated
in a manner supporting cell cycle arrest. Genes, whose
products are involved in the transition from G1 to S-phase
appeared to be downregulated, such as cyclins (CCNA2,
CCNE2,  CCNF),  cyclin-dependent kinase 2 (CDK2) and
transcription regulators (E2F2,  PCNA,  SKP2), whereas
transcription of inhibitory genes cyclin G2 (CCNG2),
GADD45A  (growth arrest and DNA-damage-inducible,
alpha) and p21cip1  (cyclin-dependent kinase inhibitor 1A,
CDKN1A) was increased. Elevated levels of CCNG2, cyclin
B1 interacting protein 1 (CCNB1IP1),  forkhead box O3A
(FOXO3A), GADD45A and p21cip1 genes as well as down-
regulation of cyclin A2 (CCNA2) and CDK2 provided evi-
dence that cell cycle progression might be additionally
arrested at the G2/M-checkpoint. The level of various
DNA replication related genes (CDC6,  CDT1,  FEN1,
MCM2,  MCM3,  MCM4,  MCM5,  MCM7,  MCM10,  Pfs2,
RFC3) was also reduced, thereby suggesting a reduction in
the replication rate. All cell cycle related effects are sum-
marized in Figure 5, which shows a cell cycle diagram
from GenMAPP (Gene Map Annotator and Pathway Pro-
filer, Gladstone Institutes, University of San Francisco,
San Francisco, CA) [38], in which up- and downregulated
genes are marked.
Apoptosis
In addition to the regulation of genes involved in prolifer-
ation control, we also observed regulation of apoptosis-
linked genes in a pro-apoptotic manner, indicating that
the extract could sensitize breast cancer cells for apoptotic
events. An increase in apoptotic events would also con-
tribute to the decrease in cellular proliferation observed.
In cells treated with black cohosh the transcript of the
apoptosis inhibitor survivin (baculoviral IAP repeat-con-
taining 5, BIRC5) was downregulated, whereas genes cod-
ing for apoptosis-inducing and -supporting products
(BNIP3L,  TNFRSF10B,  TP53INP1) were increased.
FOXO3A, GADD45A, GDF 15 (growth differentiation factor
15) and p21cip1, whose mRNA levels increased, are also
connected with apoptosis in addition to their role in cell
cycle control. Transcript of tyrosyl-tRNA synthetase
(YARS), whose secretion is linked to apoptotic events
Proliferation assay: Effects on growth rate of MCF-7 cells Figure 2
Proliferation assay: Effects on growth rate of MCF-7 cells. 
MCF-7 cells were treated with (A) dichloromethane extract 
of black cohosh rhizome, (B) actein or (C) mixture of agly-
cons derived from cycloartane glycosides. Controls (100% 
proliferation) contained 0.1% DMSO. After 120 h cell 
number was determined by MTT dye-reduction assay. Rela-
tive proliferation data are presented as means ± SD (n = 3–
6). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control (Student's t-
test).BMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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Functional categories of genes regulated in MCF-7 cells after 24 h incubation with black cohosh extract Figure 3
Functional categories of genes regulated in MCF-7 cells after 24 h incubation with black cohosh extract. Genes were grouped 
in 5 large groups (Apoptosis, Proliferation, General Growth, Signaling & Transport, Metabolism), some consisting of subgroups. 
Genes that are not clearly associated with these groups are summarized in the category others. The category stress response 
contains genes also grouped into one of the 6 main classes. Each bar represents the number of genes that were up- (dark) or 
downregulated (white) in the respective group.
Summary of effects of black cohosh in MCF-7 cells at mRNA level observed with the microarray experiment Figure 4
Summary of effects of black cohosh in MCF-7 cells at mRNA level observed with the microarray experiment. ↓ represents inhi-
bition, ↑ represents stimulation.BMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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Table 2: List of selected genes regulated by black cohosh extract in MCF-7 cells. Genes are listed with symbol, GenBank accession 
number and fold changes vs. DMSO control of two independent microarray experiments. Genes in bold are associated to stress 
response. Those written in italics have been verified by real-time RT-PCR. A full list with all 431 genes is available [see Additional file 
1].








DNA-damage-inducible transcript 4 DDIT4 NM_019058 5.1 5.6
P8 protein (candidate of metastasis 1) P8 AF135266 4.4 2.7
Tumor protein p53 inducible nuclear protein 1 TP53INP1 AW341649 3.5 3.1
Tumor necrosis factor receptor superfamily, member 10b TNFRSF10B AF016266 2.5 2.7
Immediate early response 3 IER3 NM_003897 2.0 1.9
BCL2/adenovirus E1B 19 kda interacting protein 3-like BNIP3L AL132665 1.8 1.6
Helicase, lymphoid-specific HELLS AI650364 -2.8 -2.7
Baculoviral IAP repeat-containing 5 (survivin) BIRC5 AA648913 -3.1 -2.0
PROLIFERATION
Cell cycle/Proliferation
Growth differentiation factor 15 GDF15 AF003934 6.0 4.5
Vascular endothelial growth factor VEGF AF022375 4.6 4.2
Cyclin G2 CCNG2 AW134535 2.8 2.3
DNA-damage-inducible transcript 3 (CHOP-10, GADD153) DDIT3 BC003637 2.6 2.7
RAS, dexamethasone-induced 1 RASD1 AF069506 2.6 2.4
Sestrin 2 SESN2 BF131886 2.4 2.8
Growth arrest and DNA-damage-inducible, alpha GADD45A NM_001924 2.2 2.6
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A NM_000389 1.8 1.6
Forkhead box O3A FOXO3A AV725666 1.8 1.9
Cyclin B1 interacting protein 1 CCNB1IP1 NM_021178 1.6 1.6
Cyclin-dependent kinase 7 CDK7 L20320 1.6 1.6
Cyclin F CCNF U17105 -1.5 -1.9
S-phase kinase-associated protein 2 (p45) SKP2 BC001441 -1.6 -1.6
Chromatin assembly factor 1, subunit A (p150) CHAF1A BF062223 -1.7 -1.6
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase PKMYT1 NM_004203 -1.8 -1.6
E2F transcription factor 2 E2F2 AL561296 -2.2 -1.6
Kinetochore protein Spc24 Spc24 AI469788 -2.2 -1.8
Cyclin A2 CCNA2 NM_001237 -2.3 -1.5
Proliferation-related Ki-67 antigen MKI67 AU152107 -2.3 -1.9
Cyclin E2 CCNE2 AF112857 -2.6 -3.0
E2F transcription factor 7 E2F7 AI341146 -2.7 -2.1
Kinesin family member 11 (Eg5) KIF11 NM_004523 -2.7 -1.7
DNA replication, repair and synthesis
Recq protein-like 4 RECQL4 NM_004260 -1.7 -1.7
Cyclin-dependent kinase 2 CDK2 AB012305 -2.1 -1.5
Minichromosome maintenance deficient 3 (S. Cerevisiae) MCM3 NM_002388 -2.1 -1.8
CDC6 cell division cycle 6 homolog (S. Cerevisiae) CDC6 NM_001254 -2.5 -1.6
DNA replication factor CDT1 AF321125 -2.5 -1.7
BRCA1 interacting protein C-terminal helicase 1 BRIP1 AF360549 -2.6 -1.7
Minichromosome maintenance deficient 5, cell division cycle 46 (S. Cerevisiae) MCM5 AA807529 -2.6 -1.7
Minichromosome maintenance deficient 7 (S. Cerevisiae) MCM7 AF279900 -2.7 -1.8
Ubiquitin-like, containing PHD and RING finger domains, 1 UHRF1 AK025578 -2.7 -2.7
Thymidine kinase 1, soluble TK1 BC007986 -2.8 -1.7
Proliferating cell nuclear antigen PCNA NM_002592 -2.9 -1.9
Replication factor C (activator 1) 3, 38 kda RFC3 NM_002915 -3.0 -1.7
Minichromosome maintenance deficient 2, mitotin (S. Cerevisiae) MCM2 NM_004526 -3.1 -1.6
DNA replication complex GINS protein PSF2 Pfs2 BC003186 -3.3 -1.5
Flap structure-specific endonuclease 1 FEN1 NM_004111 -3.4 -2.5
Minichromosome maintenance deficient 4 (S. Cerevisiae) MCM4 AI859865 -3.4 -2.4
Thymidylate synthetase TYMS AB077208 -3.4 -2.4BMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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ASF1 anti-silencing function 1 homolog B (S. Cerevisiae) ASF1B NM_018154 -3.5 -2.1
GENERAL GROWTH
Protein processing
Chromosome 1 open reading frame 24 C1orf24 AF288391 4.9 5.1
Seryl-tRNA synthetase SARS AU147785 4.4 4.0
DnaJ (Hsp40) homolog, subfamily C, member 10 DNAJC10 BG168666 3.1 1.9
DnaJ (Hsp40) homolog, subfamily B, member 9 DNAJB9 AL080081 2.9 2.3
Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain 
member 1
HERPUD1 AF217990 2.5 2.0
Tryptophanyl-tRNA synthetase WARS NM_004184 2.5 2.2
MAP kinase-interacting serine/threonine kinase 2 MKNK2 NM_017572 2.4 2.0
Eukaryotic translation initiation factor 4E binding protein 1 EIF4EBP1 AB044548 2.3 1.8
Stress 70 protein chaperone, microsome-associated, 60 kda STCH NM_006948 2.3 2.7
Eukaryotic translation initiation factor 2-alpha kinase 3 (syn. PERK) EIF2AK3 NM_004836 2.2 1.7
Methionine-tRNA synthetase MARS AA621558 2.2 2.2
Microtubule-associated protein 1 light chain 3 beta MAP1LC3B AF183417 2.2 1.9
Tyrosyl-tRNA synthetase YARS AW245400 2.0 1.7
Cysteinyl-tRNA synthetase CARS AI769685 1.9 2.0
Isoleucine-tRNA synthetase IARS NM_013417 1.9 2.0
F-box only protein 11 FBXO11 AL117620 1.9 1.7
Ubiquitin protein ligase E3 component n-recognin 1 UBR1 AV715153 1.9 1.8
Glutamyl-prolyl-tRNA synthetase EPRS NM_004446 1.8 1.7
Heat shock 70 kda protein 5 (glucose-regulated protein, 78 kda) HSPA5 AF216292 1.8 1.6
Transducin (beta)-like 1X-linked TBL1X AW968555 1.8 1.9
Ubiquitin specific protease 3 USP3 AF077040 1.8 1.8
Eucaryotic translation initiation factor 1 EIF1 AF083441 1.7 1.7
Glycyl-tRNA synthetase GARS D30658 1.7 2.3
SUMO1/sentrin specific protease 6 SENP6 AF306508 1.7 1.6
APG12 autophagy 12-like (S. Cerevisiae) APG12L BE965998 1.6 1.7
Ubiquitin-fold modifier 1 Ufm1 NM_016617 1.6 1.6
Heat shock 70 kda protein 2 HSPA2 U56725 -1.7 -1.9
F-box only protein 5 (early mitotic inhibitor 1) FBXO5 AK026197 -2.0 -1.7
Ubiquitin-conjugating enzyme E2C UBE2C NM_007019 -2.0 -1.6
Transcription
Basic helix-loop-helix domain containing, class B, 2 BHLHB2 NM_003670 3.6 2.6
Trinucleotide repeat containing 9 TNRC9 AK025084 3.4 2.1
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 CITED2 AF109161 3.1 1.5
CCAAT/enhancer binding protein (C/EBP), beta CEBPB AL564683 2.4 2.3
CCAAT/enhancer binding protein (C/EBP), gamma CEBPG NM_001806 2.2 2.4
Junction-mediating and regulatory protein JMY BF447037 2.2 1.6
Endothelial PAS domain protein 1 (Hypoxia-inducible factor 2, alpha) EPAS1 AF052094 2.1 1.9
Nuclear factor (erythroid-derived 2)-like 2 NFE2L2 NM_006164 2.0 1.5
Activating transcription factor 3 ATF3 NM_001674 1.8 2.0
Activating transcription factor 4 ATF4 NM_001675 1.7 1.5
Early growth response 1 EGR1 AI459194 1.7 4.7
Nuclear factor (erythroid-derived 2)-like 1 NFE2L1 NM_003204 1.6 1.6
Chromobox homolog 4 (Pc class homolog, Drosophila) CBX4 AI570531 1.5 1.8
Kruppel-like factor 4 (gut) KLF4 BF514079 1.5 1.8
Zinc finger protein 36, C3H type-like 2 ZFP36L2 AI356398 -3.1 -2.1
Cell organization, adhesion & structure and cytoskeleton
Decay accelerating factor for complement (CD55, Cromer blood group system) DAF NM_000574 3.6 3.3
Ras homolog gene family, member B RHOB AI263909 -1.8 -1.6
SIGNALING AND TRANSPORT
Receptors & Signal transduction
Table 2: List of selected genes regulated by black cohosh extract in MCF-7 cells. Genes are listed with symbol, GenBank accession 
number and fold changes vs. DMSO control of two independent microarray experiments. Genes in bold are associated to stress 
response. Those written in italics have been verified by real-time RT-PCR. A full list with all 431 genes is available [see Additional file 
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Unc-5 homolog B (C. Elegans) UNC5B AK022859 3.3 2.1
Stanniocalcin 2 STC2 BC000658 2.6 2.3
TRAF family member-associated NFKB activator TANK U59863 2.2 2.3
Interferon gamma receptor 1 IFNGR1 NM_000416 2.1 1.6
Mitogen-inducible gene 6 MIG-6 AL034417 2.1 2.5
Ras association (ralgds/AF-6) domain family 3 RASSF3 AI628605 2.0 1.5
Aryl hydrocarbon receptor AHR NM_001621 1.8 1.8
Tribbles homolog 1 (Drosophila TRIB1 NM_025195 1.7 1.6
Tribbles homolog 3 (Drosophila) TRIB3 NM_021158 1.7 1.6
Aryl hydrocarbon receptor nuclear translocator-like ARNTL AB000815 1.6 1.8
Casein kinase 1, gamma 3 CSNK1G3 NM_004384 1.5 1.6
Hypoxia-inducible factor 1, alpha subunit HIF1A NM_001530 1.5 1.5
c-Jun N-terminal kinase 1 (mitogen-activated protein kinase 8, MAPK8) JNK1 AU152505 1.5 1.5
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide YWHAH NM_003405 -1.8 -1.9
Estrogen receptor, alpha ESR1 NM_000125 -2.0 -1.8
Transport
Solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 SLC7A11 AA488687 6.2 5.7
Potassium voltage-gated channel, Isk-related family, member 4 KCNE4 AI002715 3.1 2.1
Solute carrier family 7 (cationic amino acid transporter, y+ system), member 5 SLC7A5 AB018009 2.3 2.0
Solute carrier family 38, member 2 SLC38A2 NM_018976 2.0 2.0
Ferritin H FTH1 AA083483 1.9 1.9
Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 SLC1A4 AI889380 1.6 1.6
METABOLISM
Oxidoreductase activity
Cytochrome P450, family 1, subfamily A, polypeptide 1 CYP1A1 NM_000499 12.4 3.5
Aldo-keto reductase family 1, member C1 (20-alpha (3-alpha)-hydroxysteroid dehydrogenase) AKR1C1 M33376 5.5 2.3
Aldehyde dehydrogenase 1 family, member L2 ALDH1L2 AI654224 5.0 2.2
Cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 NM_000104 4.1 2.7
Heme oxygenase (decycling) 1 HMOX1 NM_002133 3.3 2.1
Glutaredoxin (thioltransferase) GLRX AF162769 3.0 1.9
Sterol-C4-methyl oxidase-like SC4MOL AV704962 2.5 2.4
Aspartate beta-hydroxylase ASPH AF289489 2.4 2.2
5-Methyltetrahydrofolate-homocysteine methyltransferase reductase MTRR NM_024010 2.3 2.2
Methylene tetrahydrofolate dehydrogenase (NAD+ dependent) MTHFD2 NM_006636 1.9 2.0
Sterol-C5-desaturase SC5DL D85181 1.5 1.6
Cytochrome P450, family 51, subfamily A, polypeptide 1 (Sterol 14-alpha-demethylase) CYP51A1 NM_000786 1.6 1.6
Farnesyl-diphosphate farnesyltransferase 1 (Squalene synthase) FDFT1 AA872727 1.6 1.7
3-Hydroxy-3-methylglutaryl-Coenzyme A reductase HMGCR AL518627 1.8 1.7
Biosynthesis/Catabolism
Asparagine synthetase ASNS NM_001673 3.7 4.1
Acyl-coa synthetase long-chain family member 1 ACSL1 NM_021122 2.6 2.2
Phosphoenolpyruvate carboxykinase 2 (mitochondrial) PCK2 NM_004563 2.5 3.3
Spermidine/spermine N1-acetyltransferase SAT BE326919 1.6 1.8
OTHERS
Metastasis associated in lung adenocarcinoma transcript 1 MALAT-1 BG534952 11.0 3.1
S100 calcium binding protein P S100P NM_005980 5.8 5.1
Gastric-associated differentially-expressed protein YA61P, drug sensitive protein 1 --- AF220415 5.6 2.1
Hypothetical protein LOC222171 LOC222171 AI347918 5.1 3.6
Brain expressed X-linked 2 BEX2 AF251053 4.6 3.6
Myozenin 2 (calcisarcin 1) MYOZ2 AI475544 4.5 3.8
WD40 repeat protein Interacting with phosphoinositides of 49 kda WIPI49 AW052084 3.5 2.1
SLIT and NTRK-like family, member 6 SLITRK6 AI680986 3.4 2.4
Table 2: List of selected genes regulated by black cohosh extract in MCF-7 cells. Genes are listed with symbol, GenBank accession 
number and fold changes vs. DMSO control of two independent microarray experiments. Genes in bold are associated to stress 
response. Those written in italics have been verified by real-time RT-PCR. A full list with all 431 genes is available [see Additional file 
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[39], was upregulated. Downregulation of lymphoid-spe-
cific helicase (HELLS), as observed in our experiments, has
been reported to be associated with apoptosis [40]. The
upregulation of c-Jun N-terminal kinase 1 (JNK1 = MAPK8)
and DNA-damage-inducible transcript 3 (DDIT3 = CHOP =
GADD153), as observed in our experiments, have been
reported as related to stress-induced apoptosis [41,42]. p8
Protein (p8), immediate early response 3 (IER3) and DNA-
damage inducible transcript 4 (DDIT4, also known as
REDD1 or RTP801), whose transcript was strongly upreg-
ulated, are known to be expressed under cellular stress
(described later) and have been associated with both pro-
and anti-apoptotic events [43-46].
Stress response
In relation to the results above, overexpression of tran-
scripts involved with response to cellular stress was highly
statistically significant after treatment with black cohosh
extract. Among different functional categories we identi-
fied some 40 transcripts associated with metabolic stress
response such as hypoxia [47], mal- or unfolded protein
response in the endoplasmic reticulum [48,49] or starva-
tion for amino acids or glucose [50,51] (Figure 6). Tran-
Cell cycle pathway diagram obtained from GenMAPP (Gene Map Annotator and Pathway Profiler, Gladstone Institutes, Uni- versity of San Francisco, San Francisco, CA [38] Figure 5
Cell cycle pathway diagram obtained from GenMAPP (Gene Map Annotator and Pathway Profiler, Gladstone Institutes, Uni-
versity of San Francisco, San Francisco, CA [38]. Proteins involved in cell cycle control are displayed from left to right as cell 
cycle progresses from G1 through S and G2 to M-phase. Genes with boxes marked black were upregulated. Genes marked 
with grey boxes were downregulated.BMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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script of hypoxia inducible factor 1α (HIF1α; HIF1A), a
key regulator in hypoxia, was upregulated. A heterodimer
of HIF1α/ARNT (HIF1) binds to hypoxia-responsive ele-
ments (HREs), thereby regulating the expression of
hypoxia-response genes. Vascular endothelial growth factor
(VEGF), heme oxygenase 1 (HMOX1), basic helix-loop-helix
domain containing, class B, 2 (BHLHB2), p21cip1 and DDIT4
– these transcripts were also upregulated – are known to
be direct target genes [47,52,53]. A hypoxia response
pathway via mTOR (mammalian target of rapamycin)
including inactivation of EIF4EBP1 (Eukaryotic transla-
tion initiation factor 4E binding protein 1) and finally
resulting in increased mRNA translation is known to be
inhibited by DDIT4 [52]. This could explain the increase
of EIF4EBP1 mRNA we observed in our experiment. The
increases of CCAAT/enhancer binding protein, beta
(CEBPB),  endothelial PAS domain protein 1
(EPAS1=HIF2α), early growth response 1 (EGR1) and sestrin
2 (SESN2) mRNA are also related to hypoxia [53,54].
Furthermore, we observed regulation of genes related to
endoplasmic reticulum stress response (unfolded protein
response, UPR), which involves the activation of three dif-
ferent pathways. Transcription of c-Jun N-terminal kinase
1 (JNK1 = MAPK8) was upregulated in our experiment.
JNK1 is a target of one UPR-pathway and its activation
may lead to apoptosis [42,55]. Phosphorylation of
eukaryotic translation initiation factor 2 α (eIF2α) at
Stress response pathways affected by black cohosh at the transcriptional level Figure 6
Stress response pathways affected by black cohosh at the transcriptional level. Genes marked by boxes were regulated in 
MCF-7 cells after treatment with black cohosh extract. ↑ represents up-regulation, ↓ represents down-regulation. (Abbrevia-
tions: ATF6, activating transcription factor 6; XBP1, x box binding protein 1; IRE1α, Serine/threonine-protein kinase/endoribo-
nuclease, Inositol-requiring 1).BMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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Ser51 is involved not only in UPR but also in responses to
hypoxia, nutrient deprivation and other cellular stresses.
Hence, this evolutionarily conserved pathway has been
termed the integrated stress response (ISR) [41,52]. PERK
(EIF2AK3, eukaryotic translation initiation factor 2-alpha
kinase  3), whose mRNA-level was increased by black
cohosh treatment, is a kinase linking hypoxia stress
reponse and UPR to eIF2α-phosphorylation, whereas
amino acid and glucose starvation response acts via GCN2
kinase. As a consequence of eIF2α-phosphorylation the
translation of most mRNAs is inhibited, but paradoxically
the translation of activating transcription factor 4 (ATF4) is
increased. We observed an upregulation of the ATF4 gene
as well as various ATF4-induced downstream target genes,
e.g. ASNS  (asparagine synthetase),  ATF3  (activating tran-
scription factor 3), CHOP, GADD45A, HERPUD1 (homo-
cysteine-inducible, endoplasmic reticulum stress-inducible,
ubiquitin-like domain member 1), HSPA5 (heat shock 70 kDa
protein 5). Gene products of these transcripts are involved
in cell survival and tumorigenesis as well as apoptotic
events [42,49,56].
Protein turnover
In the context of mis- or unfolded protein response some
other processes of protein turnover are affected by black
cohosh extract. The expression levels of various ubiquitin
cycle-related genes (FBOX5, FBOX11, MAP1LC3B, SENP6,
TBL1X, UBE2C, UBR1, Ufm1, USP3) were influenced by
black cohosh. Some of these transcripts code for products
involved with cell cycle progression and were regulated in
a cell cycle arresting manner, emphasizing our results
described above. Inhibitory CCNB1IP1 was upregulated,
whereas SKP2 (S-phase kinase-associated protein 2; p45) and
UHRF1 (Ubiquitin-like, containing PHD and RING finger
domains, 1) were downregulated. Furthermore, mRNA-
levels of eight different aminoacyl-tRNA synthetases
(CARS, EPRS, GARS, IARS, MARS, SARS, WARS, YARS)
were upregulated.
Oxidoreductases
In response to black cohosh treatment, transcripts of sev-
eral oxidoreductases involved with metabolism of xenobi-
otics were affected. In some cases we observed strong
induction. The most prominent upregulation of all Cim-
cifuga regulated genes occurred for CYP1A1 (cytochrome
P450, family 1, subfamily A, polypeptide 1). In the microar-
ray experiments the increase was 12.4 and 3.5 fold, while
RT-PCR gave even higher changes (28.5 ± 14.0 fold, p <
0.01 and 19.2 ± 10.9 fold, p < 0.05). This was accompa-
nied by a marked but lower increase of CYP1B1 (cyto-
chrome P450, family 1, subfamily B, polypeptide 1). Both
enzymes are known to be activated by xenobiotics
through the aryl hydrocarbon receptor pathway. Tran-
script of heme oxygenase 1 (HMOX1), an essential
enzyme in heme catabolism and a direct target of HIF1
(see stress response), was also upregulated. Finally, tran-
scripts of several enzymes of the cholesterol biosynthesis
pathway (CYP51A1, FDFT1, HMGCR, SC4MOL, SC5DL)
were marginally increased.
Receptors
Interestingly, transcription of the aryl hydrocarbon recep-
tor (AhR) which regulates expression of the CYPs, was also
increased. Furthermore, we observed a downregulation of
the estrogen receptor α gene (ESR1). This regulation has
already been reported in response to hypoxic stress [57].
mRNAs coding for interferon gamma receptor 1
(IFNGR1) appeared to be upregulated. The latter pro-
motes effects of interferon γ, whose antitumor activity has
previously been reported [58].
Others
Within this category, two tumor-associated transcripts
showed largest upregulation. MALAT-1 (metastasis in lung
adenocarcinoma transcript 1), a recently identified noncod-
ing RNA, has been shown to be activated in early-stage
lung cancer. High-level expression is associated to low sur-
vival rates of patients due to high risk to develop metasta-
tis [59]. S100P  (S100 calcium binding protein P) was
reported as marker of breast cancer initiation. Expression
of S100P as well as FTH1 (Ferritin H), an iron-binding
protein, whose transcript was also upregulated by black
cohosh, is associated to immortalization and transforma-
tion of breast epithelial cells [60].
Comparison of the expression pattern of black cohosh 
with tamoxifen and E2
Expression profiles with 17β-estradiol and the estrogen
receptor-antagonist tamoxifen were investigated in paral-
lel to compare the patterns with the black cohosh extract.
After treatment with 1 nM E2 146 transcripts met our
selection criteria, among these known estrogen-regulated
genes such as insulin-like growth factor binding protein 4
(IGFBP4) or GREB1 protein (GREB1). The latter transcript
was strongly upregulated (microarray: 21.7 and 10.4 fold;
RT-PCR: 26.6 ± 10.1, p < 0.05 and 15.4 ± 5.7, p < 0.05).
With 10 µM tamoxifen 49 genes were observed to be reg-
ulated. Figure 7 shows the intersection of expression pat-
terns of black cohosh, E2 and tamoxifen. Among a total of
39 genes that were regulated both under black cohosh and
E2 treatment, 30 transcripts were affected in opposite
directions (anti-correlated). In contrast, a comparison of
black cohosh and tamoxifen revealed a correlated regula-
tion of 32 transcripts. This is quite surprising given that
only 49 genes were considered regulated in response to
tamoxifen. Hence, the expression profile of black cohosh
was more related to tamoxifen. Since E2 stimulated and
tamoxifen inhibited proliferation of MCF-7 cells in our
assay, it was not surprising that most genes in the intersec-
tions are related to cell cycle regulation and apoptosis. BMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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Among the genes associated with cell cycle arrest and
apoptosis that were regulated in all treatments, the two
cell cycle inhibitory transcripts cyclin G2 (Figure 8) and
tumor protein p53 inducible nuclear protein 1 (TP53INP1)
were both upregulated by black cohosh and tamoxifen
and downregulated by E2. Apart from ESR1, which was
downregulated with E2 and black cohosh treatment (Fig-
ure 8), and VEGF, which can be considered to be regulated
via hypoxia response pathways, no gene affected by black
cohosh is known to contain estrogen responsive elements
(ERE) in the promoter region.
Effects of actein and the cycloartane aglycon mixture
To identify active principles in black cohosh, MCF-7 cells
were treated with the major cycloartane glycoside actein
and a mixture of cycloartenol aglycons under the same
conditions as in the microarray experiments, at concentra-
tions corresponding to the IC50 values determined in the
proliferation assay. We used real-time RT-PCR to deter-
mine the expression levels vs. DMSO control of the 13
genes selected on the basis of the microarray experiments:
baculoviral IAP repeat-containing 5 (BIRC5),  cyclin E2
(CCNE2),  cyclin G2 (CCNG2),  cytochrome P450 1A1
(CYP1A1), cytochrome P450 1B1 (CYP1B1), DNA-damage-
inducible transcript 4 (DDIT4), DnaJ (Hsp40) homolog, sub-
family B, member 9 (DNAJB9), E2F transcription factor 2
(E2F2), estrogen receptor α (ESR1), growth arrest and DNA-
damage-inducible, alpha (GADD45A), metastasis associated
in lung adenocarcinoma transcript 1 (MALAT-1), proliferating
cell nuclear antigen (PCNA) and vascular endothelial growth
factor (VEGF). Upon treatment with actein and the agly-
con mixture, all transcripts appeared to be regulated in the
same direction and, in a majority of cases, in a compara-
Gene expression levels of cyclin G2 (CCNG2) and estradiol receptor α (ESR1) in MCF-7 cells after 24 h treatment with black  cohosh extract (15 µg/ml), the triterpene glycoside actein (20 µM), the triterpene aglycon mixture (30 µM), tamoxifen (10 µM)  and estradiol (1 nM) Figure 8
Gene expression levels of cyclin G2 (CCNG2) and estradiol receptor α (ESR1) in MCF-7 cells after 24 h treatment with black 
cohosh extract (15 µg/ml), the triterpene glycoside actein (20 µM), the triterpene aglycon mixture (30 µM), tamoxifen (10 µM) 
and estradiol (1 nM). For the treatments with extract, tamoxifen and estradiol, results obtained with microarrays (Array) and 
real-time RT-PCR (PCR) are shown. For actein (ACT) and the aglycons (AGL) expression levels were determined by real-
time RT-PCR. Bars represent gene expression levels as fold changes calculated versus DMSO control. RT-PCR measurements 
were done at least in triplicate. The data are presented as means ± SD (*p < 0.05, **p < 0.01, ***p < 0.001: gene expression 
statistically significantly different from DMSO control, calculated by Student's t-test).
Overlap of expression profiles Figure 7
Overlap of expression profiles. Numbers within the 3 circles 
represent the genes that were differentially expressed 
according to our filters after 24 h treatment of MCF-7 cells 
with Cimicifuga racemosa (black cohosh) extract (CR), 17β-
estradiol (E2) or tamoxifen (TAM). Numbers within the 
intersections represent genes regulated with both of the 
respective treatments or – in the middle – all 3 different 
treatments. For every intersection genes regulated in the 
same direction up or down (correlated) are marked with (+). 
Genes regulated in opposite directions (anti-correlated) are 
marked with (-).BMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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ble order of magnitude as with black cohosh treatment
(Figures 8 and 9). In general, treatment with actein
resulted in a slightly weaker regulation of the expression
levels than treatment with the black cohosh extract. In
contrast, the treatment with the aglycon mixture caused a
marginally stronger up- or downregulation of some genes,
such as CCNE2, DNAJB9, E2F2, ESR1 and GADD45A. Also
the AhR target genes CYP1A1 and CYP1B1 were upregu-
Gene expression levels of selected genes in MCF-7 cells after 24 h treatment with black cohosh extract (15 µg/ml), the triter- pene glycoside actein (20 µM) or the triterpene aglycon mixture (30 µM) Figure 9
Gene expression levels of selected genes in MCF-7 cells after 24 h treatment with black cohosh extract (15 µg/ml), the triter-
pene glycoside actein (20 µM) or the triterpene aglycon mixture (30 µM). For extract treatment results obtained with micro-
arrays (Array) and real-time RT-PCR (PCR) are shown. For actein (ACT) and the aglycons (AGL) expression levels were 
determined by real-time RT-PCR. Bars represent gene expression levels as fold changes calculated versus DMSO control. RT-
PCR measurements were done at least in triplicate. The data are presented as means ± SD (*p < 0.05, **p < 0.01, ***p < 0.001: 
gene expression statistically significantly different from DMSO control, calculated by Student's t-test).BMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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lated by the aglycon mixture and with actein albeit at a
lower level.
Discussion
We performed the first gene expression profiling experi-
ment with rhizomes of Cimicifuga racemosa (black
cohosh) to identify molecular effects in the human breast
cancer cell line MCF-7. In initial experiments analyzing
cell proliferation we observed growth inhibition in
response to treatment with a lipophilic extract of black
cohosh, the major cycloartane-type triterpene glycoside
actein and a cycloartane aglycon mixture. IC50 values were
comparable to previously reported results [22-24].
Effects of a black cohosh extract on gene expression in
MCF-7 cells were determined by means of Affymetrix
GeneChip® Human Genome U133 Plus 2.0 arrays, ena-
bling almost complete analysis of the transcriptome. After
treatment of MCF-7 cells for 24 h with the black cohosh
extract at the IC50 concentration (15 µg/ml) changes of the
expression levels of 431 genes were detected using highly
stringent selection criteria. Random permutation of gene
expression profiles showed a mean of 22 to 32 regulated
probe sets in our data set with our selection criteria indi-
cating a false positive rate of about 5%.
Comparing the expression patterns, action of black
cohosh is opposite to estradiol and more similar to
tamoxifen regarding proliferation and cell survival. How-
ever, the effect of black cohosh treatment appears more
complex, as significantly more genes were regulated than
either with E2 or tamoxifen. The genes regulated by black
cohosh did not include well-known estrogen-regulated
genes, with the exception of ESR1 (the estrogen recptor α
gene) and VEGF  which both could be regulated via
hypoxia response. In contrast, a wider range of cellular
pathways and targets were affected by black cohosh but
not E2 or tamoxifen. Hence, action of black cohosh in
MCF-7 cells seems to be neither estrogenic nor antiestro-
genic but rather multifacetted. Because MCF-7 is a model
for determining estrogenic or antiestrogenic effects, we
can conclude that the benefical effects of black cohosh in
alleviating postmenopausal complaints might be rather
due to central nervous action via dopamine, serotonin or
µ opioidic receptors.
Among all regulated genes, those related to the functional
categories of proliferation (cell cycle and DNA replication)
and stress response (including members of different func-
tional categories) were found to be highly significantly
overrepresented, and these groups appear to be intercon-
nected. Given that many genes were regulated at a lower
level and, therefore, excluded by the stringent filter set-
ting, a statistically highly significant accumulation of
genes in these functional categories emphasizes the signif-
icance of our results.
The cell cycle inhibition observed in the proliferation
experiments appears to be due to an arrest at both G1/S-
and G2/M-transition points, as indicated by an accumula-
tion of regulated genes. This finding is corroborated by
recent results of a flow cytometric analysis [24]. Several
genes involved in apoptosis appeared to be regulated,
most genes in a pro-apoptotic manner. Some genes are
related to apoptotic as well as anti-apoptotic events. These
genes are linked to different cellular stress response mech-
anisms. Altogether, the expression levels of approxima-
tively 40 genes related to stress response were affected by
black cohosh. Given the fact that results of stress response
pathways are contradictory, pro- and anti-apoptotic gene
expression may not be surprising. The main purpose of
stress response is an adaptation of the cells to stress fac-
tors, resulting in cell survival, angiogenesis and promoted
tumor growth. However, when stress reaches a certain
threshold, the protecting pathways become saturated and
cells undergo apoptosis [49]. This may explain the seem-
ingly contradictory effects observed in our experiment.
Altogether, pro-apoptotic signalling seems to outweigh.
Stress response regulation has already been previously
reported for other xenobiotics such as the cancer chemo-
protective phytochemical indole-3-carbinol (I3C) and its
physiological condensation product diindolylmethane
(DIM), whose antitumor activity has been widely investi-
gated [42]. Its influence on gene expression in different
tumor cells – among others in breast cancer cells such as
MCF-7 – shows a certain similarity to our results with
black cohosh. However, the mechanism of induced stress
response by I3C is still unknown.
In association with unfolded protein response various
transcripts of protein turnover were affected by black
cohosh. Regulation of several transcripts whose products
are involved in ubiquitinylation may be due to aug-
mented degradation of malformed proteins. Increased
mRNA levels of not less than eight different aminoacyl-
tRNA synthetases (ARSs) are not only linked to protein
synthesis. Some ARSs are rather multifunctional proteins
involved in different cellular processes [61]. For example,
the secretion of tyrosyl-tRNA synthetase (YARS) is linked
to apoptotic events [39] and tryptophanyl-tRNA syn-
thetase (WARS) has been shown to possess angiostatic
and proliferation-inhibitory activity [61].
As response to exposure to black cohosh extract a group of
transcripts coding for enzymes with oxidoreductase activ-
ity was upregulated ("response to xenobiotics"). A strong
upregulation was observed for CYP1A1, and, to a some-
what lesser extent, of CYP1B1. Apart from well-known
involvement in xenobiotic metabolism, thereby mediat-BMC Pharmacology 2007, 7:11 http://www.biomedcentral.com/1471-2210/7/11
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ing toxic and tumorigenic effects of several chemicals,
these two oxidoreductases are involved in the metabolism
of 17β-estradiol [62]. CYP1A1 metabolizes E2 to non-car-
cinogenic 2-hydroxy-E2 whereas CYP1B1 is responsible
for the formation of carcinogenic 4-hydroxy-E2. The two
enzymes are not always expressed at the same level in tis-
sues. An increased production of 2-hydroxy-E2 relative to
4-hydroxy-E2, due to a higher expression level of CYP1A1
than CYP1B1, has been suggested to be contributing to
the antitumor activity of indol-3-carbinol and, therefore,
being of clinical importance [62]. As described, we also
observed significantly stronger induction of CYP1A1 tran-
scripts than CYP1B1 with black cohosh treatment.
CYP1A1 is known as the classical target of the aryl hydro-
carbon receptor (AhR). Interestingly, the receptor has also
been upregulated with our experiment. The AhR, upon
binding of a ligand, forms a heterodimeric complex with
ARNT (aryl hydrocarbon receptor nuclear translocator)
which induces transactivation of the CYPs and other target
genes via binding to xenobiotic response elements (XREs)
in their promoter regions [63]. Classical AhR ligands and,
therefore, CYP1A1 inducers are hydrophobic and planar
or coplanar molecules of polycyclic structure. Although
the cycloartane-type triterpenoids do not satisfy these
structural requirements, gene expression of CYP1A1 was
not only induced in our experiments by black cohosh
extract but also by the cycloartane aglycons (5.0 ± 1.7 fold,
p < 0.01 and 12.2 ± 3.4 fold, p < 0.01) and, to a lower but
statistically significant extent, by actein (2.1 ± 0.8, p < 0.05
and 2.0 ± 0.2, p < 0.01). CYP1B1 was also differentially
expressed by the triterpenoids. The upregulation of
CYP1A1 and CYP1B1 expression by extract and purified
cycloartanes cannot be explained by AhR binding. Indeed,
black cohosh extract and compounds did not show any
AhR activity in a reporter gene assay [64] in rat hepatoma
H4IIE cells [see Additional file 2]. These findings are in
contradiction with previous experiments showing weak
AhR binding and transactivation activity of black cohosh
extracts. However, these experiments were carried out
with high concentrations (up to 200 µg/ml) and did not
include single compounds [20,21]. The upregulation of
CYP1A1 and CYP1B1 may be linked to activation of genes
involved with hypoxic stress response, although the con-
sequences of upregulated stress response appear some-
what contradictory. AhR and hypoxia-induced signal
transduction are connected via ARNT, and AhR and
HIF1α compete in binding to ARNT. Hypoxic conditions
reportedly inhibited AhR-dependent gene expression
[65], on the other hand, a connection between CYP1A1
induction and hypoxia-induced gene regulation in Caco2
cells has been found [66].
Besides CYP1A1 and CYP1B1, 11 other selected mRNAs
representing all regulated functional categories were
investigated by real-time RT-PCR to verify the microarray
results and to investigate the effects of the cycloartane-
type triterpenoids. Briefly, all genes were regulated by the
triterpenoids in the same direction and to a fairly compa-
rable extent than with the extract. Hence, we provide here
first evidence that cycloartane glycosides as well as their
aglycons, which are most likely formed in the intestine
prior to absorption, are putative active principles in black
cohosh.
Conclusion
In conclusion, the microarray investigation on black
cohosh in MCF-7 breast cancer cells revealed several new
interesting aspects. Gene expression "contra cell prolifera-
tion" and "pro apoptosis" emphasizes previously reported
actions of black cohosh. These effects might be a result of
stress response to hypoxic conditions, protein distur-
bances and induction of oxidoreductases, evoked by an
exposure to black cohosh extract. Regulation of other
genes, eg. induction of CYP1A1, IFNGR1 and WARS and
downregulation of ERα mRNA (ESR1) might contribute
to a putative antitumor activity of black cohosh. On the
other hand, activation of genes involved in cell survival,
angiogenesis and tumor progression, such as VEGF,
S100P,  MALAT-1  and different stress response genes,
raises questions. Since black cohosh is increasingly popu-
lar as an alternative to HRT, a thorough benefit/risk assess-
ment is required. Black cohosh preparations have been
considered as safe up to now and no serious adverse reac-
tions have been reported so far. Nonetheless, further
investigations are needed to assess the safety level and to
analyze putative antitumor applications with functional
assays and in vivo models.
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